Key facts
- Wild Bioscience’s last known valuation is $128.6M (Oct 2025).
- It has raised $76.7M; the latest was Early Stage VC ($61.1M) in Oct 2025.
- Notable investors include Innovate UK, Tech Nation Group, University of Oxford, Oxford Science Enterprises, Braavos Investment Advisers — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Wild Bioscience
- ·The full record, as it builds
Funding rounds
No funding rounds for Wild Bioscience are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Wild Bioscience
Operator of a farm productivity platform intended to develop climate-resilient, high-yield crop varieties. The company combines machine learning, gene editing, and precision breeding from wild plant evolution to identify and integrate beneficial traits into crops, enabling seed companies, agricultural producers, and research institutions to develop improved crop varieties with enhanced crop productivity and sustainability.
- Sector
- Materials and Resources
- HQ
- Abingdon, United Kingdom
- Founded
- 2021
- Employees
- 30
- Website
- wildbioscience.com/
- Ownership
- Privately Held (backing)
Wild Bioscience doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Wild Bioscience shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Wild Bioscience in its N-PORT filings yet. We sweep new filings monthly.